Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Tumor necrosis factor antagonists and cancer in patients with rheumatoid arthritis

Nature Clinical Practice Rheumatology volume 3, pages 14–15 (2007)Cite this article

Access through your institution
Buy or subscribe

boxed-textSetoguchi S et al. (2006) Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 54: 2757–2764

Data for an association between TNF antagonists and malignancy are inconclusive; physicians should discuss with patients the potential risks of TNF antagonists, including potential malignancy

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Chakravarty EF et al. (2005) Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 32: 2130–2135

    CAS  PubMed  Google Scholar 

  2. Bongartz T et al. (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systemic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295: 2275–2285

    Article  CAS  Google Scholar 

  3. Watson KD et al. (2006) Influence of anti-TNF therapy and previous malignancy on cancer incidence in patients with rheumatoid arthritis (RA): results from the BSR biologics register [abstract]. Ann Rheum Dis 65 (Suppl): S512

    Google Scholar 

  4. Askling J et al. (2005) Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 64: 1421–1426

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Rachel Murphy, Assistant Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. EL Matteson is a Professor of Medicine and a Consultant at the Division of Rheumatology, and T Bongartz is an Assistant Professor of Medicine and a Resident in Internal Medicine, at the Mayo Clinic in Rochester, MN, USA.,

    Eric L Matteson & Tim Bongartz

Authors
  1. Eric L Matteson
    View author publications

    Search author on:PubMed Google Scholar

  2. Tim Bongartz
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Eric L Matteson.

Ethics declarations

Competing interests

Eric L Matteson is a consultant, grant supporter or investigator for the following companies/organizations: Amgen, Aventis, Biogen-IDEC, Burroughs-Wellcome, Centocor/Johnson & Johnson, Genentech, Hoffman-La Roche, Human Genome Sciences, Immunex, Nastec, Novartis, Regeneron, Schering, Takeda, Wyeth and Xoma Corporation. T Bongartz is a consultant, grant supporter or investigator for the following companies/organizations: Abbott, Amgen and Wyeth.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Matteson, E., Bongartz, T. Tumor necrosis factor antagonists and cancer in patients with rheumatoid arthritis. Nat Rev Rheumatol 3, 14–15 (2007). https://doi.org/10.1038/ncprheum0376

Download citation

  • Received:

  • Accepted:

  • Issue date:

  • DOI: https://doi.org/10.1038/ncprheum0376

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing